Boehringer Ingelheim, Evotec and BioMérieux Link on AMR

German biopharma Boehringer Ingelheim, compatriot CDMO Evotec and French diagnostics firm BioMérieux have formed a joint venture to develop a new approach to fight the rise of antibiotic-resistant infections.

© Shutterstock
© Shutterstock

The new company, called Aurobac Therapeutics, will be headquartered in Lyon, France. Boehringer Ingelheim is the lead investor with €30 million, with Evotec and BioMérieux each investing €5 million. The partners did not disclose the size of their stakes in the venture.

“The rise of antibiotic-resistant infections — also called antimicrobial resistance, or AMR — is indeed a looming global crisis,” added Michel Pairet, head of Boehringer Ingelheim’s Innovation unit and member of the board of managing directors. “Antibiotic resistance kills about 1.27 million people globally every year and it has been estimated that by 2050, as many as 10 million worldwide deaths could result from AMR, making it potentially deadlier than cancer.”

The partners said current antibiotic treatment regimens lean heavily on broad-spectrum and unfocused medicines. Aurobac’s goal is to change this to a precision-led approach, using new highly effective and targeted therapies, combined with rapid diagnostics to quickly identify pathogens and their resistance patterns.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Boehringer Ingelheim

Binger Str. 173
55218 Ingelheim

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.